Skip to main content
Clinical Trials/ISRCTN10939948
ISRCTN10939948
Completed
未知

Treatment of Clinically Significative diabetic Macular Edema: influence of Bevacizumab, Triamcinolone and the combination of both plus macular grid thermal laser Photocoagulation of subthreshold

Opthalmological Foundation of the Mediterranean (Fundacion Oftalmologica del Mediterraneo) (Spain)0 sites60 target enrollmentMay 15, 2007

Overview

Phase
未知
Intervention
Not specified
Conditions
Not specified
Sponsor
Opthalmological Foundation of the Mediterranean (Fundacion Oftalmologica del Mediterraneo) (Spain)
Enrollment
60
Status
Completed
Last Updated
4 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
May 15, 2007
End Date
January 1, 2008
Last Updated
4 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Opthalmological Foundation of the Mediterranean (Fundacion Oftalmologica del Mediterraneo) (Spain)

Eligibility Criteria

Inclusion Criteria

  • 1\. Diabetic CSME not treated previously
  • 2\. Best Corrected Visual Acuity (BCVA) less than 20/40
  • 3\. Patient able to complete follow\-up
  • 4\. Controlled diabetes

Exclusion Criteria

  • 1\. Other associated ocular pathology
  • 2\. Ocular surgery three months before the inclusion
  • 3\. Participating in other interventional studies

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting
Not Applicable
Optimised treatment for pre-existing diabetic macular oedema during cataract surgeryDiabetic Macular Oedema in type 2 diabetic patients with visually significant cataractEar, Nose and ThroatCataract, diabetic macular oedema, type 2 diabetes mellitus with ophthalmic complications
ISRCTN18293240Chinese University of Hong Kong92
Active, not recruiting
Phase 1
Investigation of Eylea for patients with diabetic macular edema in an outpatient Setting.Diabetic Retinopathy and diabetic macular edema are leading causes for visual loss and blindness in young adults around the world.MedDRA version: 18.0Level: LLTClassification code 10057934Term: Diabetic macular edemaSystem Organ Class: 100000004853Therapeutic area: Diseases [C] - Eye Diseases [C11]
EUCTR2015-000959-24-ATAbteilung für Augenheilkunde, AKH Linz50
Recruiting
Phase 2
Assessment of medical treatment of diabetes on comorbid diastolic let-ventricular dysfunction observed by cardiac MRI in diabetic patientsHeart failure with diastolic dysfunction and comorbid diabetes.
JPRN-UMIN000012209Cardiology, Nagoya University50
Active, not recruiting
Not Applicable
The Most Effective Treatment Strategy for Diabetic Macular Edema.diabetic macular edemaMedDRA version: 15.0Level: LLTClassification code 10057934Term: Diabetic macular edemaSystem Organ Class: 10015919 - Eye disordersTherapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]
EUCTR2012-003652-36-NLThe Rotterdam Eye Hospital
Completed
Not Applicable
The Most Effective Treatment Strategy for Diabetic Macular Edema.diabetic macular edema1001265310015917
NL-OMON39983Oogziekenhuis Rotterdam456